biospectrumasia.com Open in urlscan Pro
2a02:4780:24:d507:f56a:bb8d:dc0e:c2da  Public Scan

Form analysis
9 forms found in the DOM

GET /search/

<form action="/search/" method="get" class="ng-pristine ng-valid">
  <input type="text" name="query" id="search_text" value="">
  <input type="submit" name="" id="search_button" value="">
</form>

---

Name: editorPickForm — POST /article-editors-pick-data

<form method="post" role="form" name="editorPickForm" action="/article-editors-pick-data" class="form-horizontal ng-pristine ng-valid">
  <div class="col-md-5">
    <img src="/cms-images/editor-picks-E-mailer.jpg" class="img-responsive" alt="Editors Pick">
  </div>
  <div class="col-md-7">
    <div class="form-group">
      <label class="control-label" for="ename">Name<span class="required"> * </span></label>
      <input type="text" name="editorPickForm[name]" class=" form-control" id="ename" required="">
    </div>
    <div class="form-group">
      <label class="control-label" for="eemail">Email<span class="required"> * </span></label>
      <input type="email" name="editorPickForm[email]" class=" form-control" id="eemail" required="">
    </div>
    <div class="form-group">
      <label class="control-label" for="ecountry">Country<span class="required"> * </span></label>
      <input type="text" name="editorPickForm[country]" class=" form-control" id="ecountry" required="">
    </div>
    <div class="form-group">
      <label class="control-label" for="eorganisation">Organisation<span class="required"> * </span></label>
      <input type="text" name="editorPickForm[organisation]" class=" form-control" id="eorganisation" required="">
    </div>
    <div class="form-group">
      <label class="control-label" for="ecountry-code">Contact Number<span class="required"> * </span></label>
      <input type="text" name="editorPickForm[contact]" class=" form-control col-md-2" id="econtact" required="">
      <span class="help-block">+Country Code-Phone Number(xxx-xxxxxxx)</span>
    </div>
    <button type="submit" class="btn btn-success">Submit</button>
  </div>
</form>

---

Name: commentForm —

<form role="form" name="commentForm" id="commentForm0" ng-controller="SiteCommentController" ng-submit="submitComment()" ng-model="commentAction" ng-init="commentAction='/comment-handle/'" class="ng-pristine ng-untouched ng-valid ng-scope">
  <div class="alert alert-success alert-dismissable" id="comment-success-box-0" style="display: none;">
    <a href="#" class="close" data-dismiss="alert" aria-label="close">×</a>
    <h3>Thank You</h3>
    <strong>Your comment has been submitted for approval.</strong><br> Please note that comments are moderated and are generally published if they are on-topic and not abusive.
  </div>
  <div class="form-group">
    <label class="sr-only" for="comment-message_0">Comment</label>
    <textarea name="comment" placeholder="Enter your comment here" class="contact-message form-control ng-pristine ng-untouched ng-valid" id="comment-message_0" ng-model="commentFormData.comment"></textarea>
  </div>
  <!-- ngIf: sessionError != '0' -->
  <button type="button" class="btn btn-success clogin-button">Log In To Comment</button>&nbsp;&nbsp; New User?&nbsp;<a class="dips-pointer cregister-button">Create Account</a>
</form>

---

Name: pollForm —

<form name="pollForm" id="pollForm" ng-controller="SitePollController" ng-submit="submitPoll()" ng-model="action" ng-init="action='/poll-handle/'" class="ng-pristine ng-untouched ng-valid ng-scope">
  <div class="col-md-12 col-centered pt">
    <input type="hidden" name="pollQuestionId" id="pollQuestionId" value="96" ng-model="pollFormData.pollQuestionId" ng-init="pollFormData.pollQuestionId='96'" class="ng-pristine ng-untouched ng-valid">
    <div class="lineb"></div>
    <div class="lineg"></div>
    <h4 class="blue">Survey Box</h4>
    <p class="blue-link">
      <a>Is the APAC region addressing accessibility and affordability of cell &amp; gene therapies?</a>
    </p>
    <p class="news-heading"></p>
    <!-- ngIf: optionData === undefined -->
    <div class="ng-scope" ng-if="optionData === undefined">
      <div class="radio">
        <label><input type="radio" name="option" id="option_245" value="245" ng-model="pollFormData.pollOptionId" class="ng-pristine ng-untouched ng-valid"> Yes</label>
      </div>
      <div class="radio">
        <label><input type="radio" name="option" id="option_246" value="246" ng-model="pollFormData.pollOptionId" class="ng-pristine ng-untouched ng-valid"> No</label>
      </div>
      <div class="radio">
        <label><input type="radio" name="option" id="option_247" value="247" ng-model="pollFormData.pollOptionId" class="ng-pristine ng-untouched ng-valid"> May be</label>
      </div>
      <div class="alert alert-danger alert-dismissable ng-hide" ng-show="isPollError == '1'" id="poll-error-box">
        <a href="#" class="close" data-dismiss="alert" aria-label="close">×</a> Please select an option to participate in the poll.
      </div>
      <!-- ngIf: pollRequestState != '0' -->
      <!-- ngIf: pollRequestState == '0' --><span class="ng-scope" ng-if="pollRequestState == '0'">
        <button type="submit" class="btn btn-primary">Vote</button>
      </span><!-- end ngIf: pollRequestState == '0' --> &nbsp;&nbsp;<a href="/poll/96/is-the-apac-region-addressing-accessibility-and-affordability-of-cell-gene-therapies">View poll results</a> &nbsp;&nbsp;<a href="/polls/">More polls</a><br><br>
    </div><!-- end ngIf: optionData === undefined -->
    <!-- ngIf: optionData !== undefined -->
    <!-- ngRepeat: optionDetail in optionData -->
    <!-- ngIf: optionData !== undefined -->
  </div>
</form>

---

Name: enquiryForm — POST

<form role="form" method="post" name="enquiryForm" id="enquiryForm" class="ng-pristine ng-valid">
  <div class="alert alert-success" id="enquiry-alert" style="display: none;"> Thanks for contacting us! We will get in touch with you shortly. </div>
  <div class="alert alert-danger" id="enquiry-error" style="display: none;"> Please fill the all fields. </div>
  <div class="alert alert-danger" id="enquiry-error-msg" style="display: none;"></div>
  <div class="form-group">
    <label class="sr-only" for="contact-name">Name</label>
    <input type="text" name="enquiryForm[name]" placeholder="Name" class="form-control" id="name">
  </div>
  <div class="form-group">
    <label class="sr-only" for="contact-email">Email</label>
    <input type="text" name="enquiryForm[email]" placeholder="Email" class="form-control" id="email">
    <span class="help-block text-danger" id="enquiry-email-error" style="display: none;">Enter a valid email address.</span>
  </div>
  <div class="form-group">
    <label class="sr-only" for="contact-subject">Phone</label>
    <input type="text" name="enquiryForm[contact]" placeholder="Phone" class="form-control" id="contact">
  </div>
  <div class="form-group">
    <label class="sr-only" for="contact-message">Message</label>
    <textarea name="enquiryForm[message]" placeholder="Message" class="form-control" id="message"></textarea>
  </div>
  <a href="javascript:;" class="color-333" id="save-enquiry-btn" data-enquiry-url="/enquiry-handle/"><button type="button" class="btn">Send message</button></a>
  <img src="/bundles/interlinksapp/assets/global/plugins/owl-carousel/assets/img/AjaxLoader.gif" id="enquiry-ajax-loader" class="hide">
</form>

---

Name: loginForm — POST /login/

<form role="form" action="/login/" method="post" name="loginForm" id="loginForm" onsubmit="return validateLogin();" class="ng-pristine ng-valid">
  <div class="alert alert-danger" id="login-error-msg" style="display: none;"></div>
  <div class="form-group">
    <label class="sr-only" for="login-email">Email id</label>
    <input type="email" name="loginForm[email]" placeholder="Email" class="form-control" id="login-email">
    <span class="help-block text-danger" id="login-email-error" style="display: none;"></span>
  </div>
  <div class="form-group">
    <label class="sr-only" for="login-password">Password</label>
    <input type="password" name="loginForm[password]" placeholder="Password" class="form-control" id="login-password">
    <span class="help-block text-danger" id="login-password-error" style="display: none;"></span>
  </div>
  <div class="row">
    <div class="col-md-12">
      <div class="form-group">
        <button class="btn btn-success col-md-12" type="submit">Sign In</button>
      </div>
    </div>
  </div>
</form>

---

Name: registrationForm — POST /registration/

<form role="form" action="/registration/" method="post" name="registrationForm" id="registrationForm" onsubmit="return validateRegistration();" class="ng-pristine ng-valid">
  <input type="hidden" value="false" id="is-email-exist">
  <input type="hidden" value="05cf70c1052486f0a592e43f419509834ae5af4e1c8bcc78489af1a5808b0f1a" name="vasadfs9ebcdefad7ce8d9">
  <div class="alert alert-danger" id="registration-error-msg" style="display: none;"></div>
  <div class="row">
    <div class="col-md-6 hide">
      <div class="form-group">
        <label class="sr-only" for="account-firstName">City</label>
        <input type="text" class="form-control" name="registrationForm[city]" id="city" placeholder="Paris">
        <span class="help-block text-danger" id="account-city-error" style="display: none;"></span>
      </div>
    </div>
    <div class="col-md-6">
      <div class="form-group">
        <label class="sr-only" for="account-firstName">First Name</label>
        <input type="text" name="registrationForm[firstName]" placeholder="First Name" class="form-control" id="account-firstName" autocomplete="off">
        <input type="hidden" value="cc78489af1a5firstName808b0f1a" name="cc78489af1a5808b0f1a">
        <span class="help-block text-danger" id="account-firstName-error" style="display: none;"></span>
      </div>
    </div>
    <div class="col-md-6">
      <div class="form-group">
        <label class="sr-only" for="account-lastName">Last Name</label>
        <input type="text" name="registrationForm[lastName]" placeholder="Last Name" class="form-control" id="account-lastName" autocomplete="off">
        <span class="help-block text-danger" id="account-lastName-error" style="display: none;"></span>
      </div>
    </div>
  </div>
  <div class="form-group">
    <label class="sr-only" for="account-email">Email ID</label>
    <input type="email" name="registrationForm[email]" placeholder="Email Id" class="form-control" id="account-email" autocomplete="off">
    <span class="help-block text-danger" id="account-email-error" style="display: none;"></span>
  </div>
  <div class="form-group">
    <label class="sr-only" for="account-password">Password</label>
    <input type="password" name="registrationForm[password]" placeholder="Password" class="form-control" id="account-password" onblur="validatePassword();" autocomplete="off">
    <span class="help-block text-danger" id="account-pass-error" style="display: none;"></span>
  </div>
  <div class="form-group">
    <label class="sr-only" for="account-confirm-password">Confirm Password</label>
    <input type="password" name="registrationForm[confirmPassword]" placeholder="Confirm Password" class="form-control" id="account-confirm-password" onblur="validatePassword();" autocomplete="off">
    <span class="help-block text-danger" id="account-password-error" style="display: none;"></span>
  </div>
  <div class="form-group">
    <label><input type="checkbox" value="Yes" name="registrationForm[is_newletter]"> Newsletter</label>
  </div>
  <div class="form-group">
    <label><input type="checkbox" value="Yes" name="registrationForm[emagazine]"> E-magazine</label>
  </div>
  <div class="form-group">
    <label><input type="checkbox" value="Yes" name="registrationForm[bio_info]"> Biospectrum Infomercial</label>
  </div>
  <div class="form-group">
    <label><input type="checkbox" value="Yes" name="registrationForm[bio_reso]"> Bio Resource</label>
  </div>
  <div class="form-group">
    <label><input type="checkbox" value="1" required=""> I accept the <a href="/pdf/terms-and-conditions.pdf" target="_blank">terms &amp; condition</a> &amp; <a href="/pdf/privacy-policy.pdf" target="_blank">Privacy policy</a></label>
  </div>
  <div class="row">
    <div class="col-md-12">
      <div class="form-group">
        <button class="btn btn-success col-md-12" type="submit">Sign Up</button>
      </div>
    </div>
  </div>
</form>

---

Name: forgotPasswordForm — POST /forgot-password/

<form role="form" action="/forgot-password/" method="post" name="forgotPasswordForm" id="forgotPasswordForm" onsubmit="return validateForgotPassword();" class="ng-pristine ng-valid">
  <input type="hidden" value="05cf70c1052486f0a592e43f419509834ae5af4e1c8bcc78489af1a5808b0f1a" name="registration_csrfs9ebcdefad7ce8d9">
  <input type="hidden" name="websitegh49ebcd78asd12a5sd">
  <div class="alert alert-danger" id="forgot-pass-error-msg" style="display: none;"></div>
  <div class="form-group">
    <label class="sr-only" for="forgot-pass-email">Email id</label>
    <input type="text" name="forgotPasswordForm[email]" placeholder="Email" class="form-control" id="forgot-pass-email">
    <span class="help-block text-danger" id="forgot-pass-email-error" style="display: none;"></span>
  </div>
  <div class="row">
    <div class="col-md-12">
      <div class="form-group">
        <button class="btn btn-success col-md-12" type="submit">Submit</button>
      </div>
    </div>
  </div>
</form>

---

Name: newsletterForm — POST /newsletter-handle/

<form role="form" action="/newsletter-handle/" method="post" name="newsletterForm" id="newsletterForm" onsubmit="return validateNewsletter();" class="ng-pristine ng-valid">
  <div class="alert alert-danger" id="newsletter-error-msg" style="display: none;"></div>
  <div class="form-group">
    <label class="sr-only" for="nl-email">Email ID </label>
    <input type="email" name="newsletterForm[email]" placeholder="Email Id" class="form-control" id="nl-email">
    <span class="help-block text-danger" id="nl-email-error" style="display: none;"></span>
  </div>
  <div class="form-group">
    <label><input type="checkbox" value="1" required=""> I accept the <a href="/pdf/terms-and-conditions.pdf" target="_blank">terms &amp; condition</a> &amp; <a href="/pdf/privacy-policy.pdf" target="_blank">Privacy policy</a></label>
  </div>
  <div class="row">
    <div class="col-md-12">
      <div class="form-group">
        <button class="btn btn-danger col-md-12" type="submit">SUBSCRIBE!</button>
      </div>
    </div>
  </div>
</form>

---

Text Content

Wednesday, 03 April 2024
 * Subscribe
 * Newsletter
 * Webinars
 * Editorial Calendar 2024
 * Media Kit




Toggle navigation
 * HOME
 * Pharma
   *   Generics
   *   Drug Discovery
   *   CMC & Manufacturing
   *   Clinical Trials
   *   New Drug Applications
 * BioTech
   *   Biologics
   *   Stem Cells
   *   Vaccines
   *   Therapeutics
 * MedTech
   *   Medical Devices
   *   Medical Diagnostic
 * BioServices
   *   Contract Research
   *   Clinical Research
   *   Contract Manufacturing
   *   Pre Clinical Development
   *   Clinical Trial Phase
 * Healthcare
   *   Digital Health
   *   COVID19
   *   Artificial Intelligence
 * Bio LAB
   *   Lab Products
   *   Lab Safety
   *   Lab Management
   *   Lab Design
 * HER Health
 * Cell & Gene
 * Specials
   *   Bio interaction
   *   Premium Article
   *   Biopreneurs
   *   Industry Insights
   *   Bio Money
   *   Bio Informatics
   *   Bio Jobs
   *   Infomercial
   *   Partner Content
   *   BioSpectrum Asia Awards 2022
 * Country
   *   Australia
   *   China
   *   India
   *   Japan
   *   Korea
   *   Malaysia
   *   New Zealand
   *   Singapore
   *   Taiwan
   *   Thailand
   *   Indonesia
   *   Vietnam
   *   North America
   *   World
   *   Middle East countries
   *   Europe
   *   SAARC




 1. BioTech
 2. Addressing Accessibility and Affordability of Cell & Gene Therapies


ADDRESSING ACCESSIBILITY AND AFFORDABILITY OF CELL & GENE THERAPIES

01 April 2024 | Analysis | By Ayesha Siddiqui

 * 
 * 
 * 
 * Share
 * 
 * 
 * 
 * 
 * 
 * 



Cell and gene therapies (CGT) are one of the hottest sectors in the
pharmaceutical industry. Quite a few companies in the field are making
remarkable advancements toward potentially curative treatments for challenging
diseases using groundbreaking science. Despite a steady stream of regulatory
approvals and promising growth prospects, the high manufacturing costs
associated with these therapies often render them inaccessible to the majority
of patients. To address this issue, companies are actively striving to
streamline and optimise the highly intricate and labour-intensive process of
cell and gene therapy manufacturing. Let’s explore further.



The most sought-after and hot sector in the pharmaceutical industry, which has
witnessed an outpouring of billions and record-breaking approvals in recent
times, is cell and gene therapy. Last year, the United States Food and Drug
Administration (US FDA) approved seven cell and gene therapy products, including
the world's first approved CRISPR gene editing therapy, Casgevy, two cell
therapy products, and the first oral faecal microbiota product, Vowst.

Globally, 30 gene therapies have been approved (including genetically modified
cell therapies). The cell and gene therapy sector has expanded tremendously,
with the number of drugs in development growing nearly six-fold from 511
development-stage candidates in 2013 to just over 3,000 in 2023, according to
Citeline’s Pharmaprojects. 

By 2025, the FDA aims to review and approve 10-20 gene and cell therapies
annually. With an increasing number of products obtaining regulatory approval in
the coming years, the market size for CGT is projected to reach $94 billion by
2030, according to Precedence Research. Oncology is anticipated to maintain its
lead as the primary indication and area of significant advancement for cell and
gene therapies, projected to account for 44 per cent of the CGT market by 2029.
Other therapeutic areas poised to derive benefits from CGT include
neurodegenerative, autoimmune, and cardiovascular diseases.

 

Asian Scenario 

The Asia Pacific region has been leading in the field of cell and gene
therapies, with several countries investing significantly in research and
development. China, in particular, has emerged as an important market for CGTs,
particularly CAR-T therapies, surpassing the USA in the number of clinical
trials conducted. The industry is considered a strategic priority by the
government, with CAR T-cell therapy clinical trials in China accounting for over
50 per cent of registered CGT studies worldwide. Currently, there are over 200
ongoing CAR-T trials in China covering a wide range of targets and indications,
from haematology-oncology to solid tumours, according to reports from Nature. 

Yescarta, developed by Fosun Kite, and relma-cel, from JW Therapeutics, stand as
China’s first regulatory-approved CAR T-cell therapies, heralding a new era for
the industry. A notable achievement is cilta-cel, developed by Legend Biotech,
which has successfully gained FDA approval, marking its global recognition.

With lower R&D development costs than in advanced markets, China is becoming an
attractive market for the development of CGT, and therefore may emerge as a
strong competitor of overseas-made CGT, notes a GlobalData report. Adding to
this momentum, Bayer AG announced the global expansion of its life science
incubator network, Bayer Co. Lab, to Shanghai, China. At the new site in China,
Bayer will collaborate with Shanghai Pharmaceuticals to focus on oncology and
CGT innovations. 

While India lags behind China in the production of cell and gene therapies, a
wave of new biotech startups is emerging to address this challenge. Immuneel
Therapeutics and ImmunoACT are currently developing CAR-T cell therapies.
ImmunoACT's NexCAR19 therapy received approval from India's Central Drug
Standards Control Organisation (CDSCO) for treating relapsed or refractory
B-cell lymphomas and leukaemia. This approval positions ImmunoACT to lead
India's indigenous CAR-T cell therapy efforts, with NexCAR19 undergoing Phase II
trials for other lymphomas and leukaemia types. Similarly, Immuneel
Therapeutics' IMN-003A CAR-T is in Phase II trials for B-cell lymphomas and
leukaemia. The successful completion of these trials holds promise in meeting
the critical need for effective cancer therapies in India. Recently, German
biotech firm Miltenyi Biotec launched operations in India, planning to establish
a centre in Hyderabad.

Singapore is emerging as a top destination for CGT manufacturing, with numerous
companies unveiling plans to set up facilities in the country. SCG Cell Therapy
is among those, announcing the establishment of a manufacturing facility and R&D
centre in Singapore. Concurrently, Biosyngen inaugurated a new cell therapy GMP
facility in Singapore, further bolstering the city-state's position in the
field. Adding to this momentum, the Advanced Cell Therapy and Research Institute
Singapore (ACTRIS) recently opened a new 2,000 sqm cell therapy facility to
address the growing clinical demand for CGT treatments in Singapore. Thermo
Fisher Scientific has also contributed to Singapore's CGT landscape, launching a
Cell Therapy Collaboration Center Program aimed at advancing cell therapy
initiatives across the Asia-Pacific region. 

Australia also aims to become a hub for these therapies. AusBiotech and
Medicines Australia are driving the Cell and Gene Catalyst initiative to
accelerate development and commercialisation in Australia, with a focus on
strengthening the ecosystem and collaborating with industry leaders. The country
also launched Australia's National Cell and Gene Manufacturing Blueprint,
outlining a strategic approach to establish the country as a regional leader.
The blueprint emphasises infrastructure and workforce development to bolster
manufacturing capabilities and capacity.

 

Addressing Prohibitive Costs 

Cell and gene therapies offer hope for life-threatening debilitating conditions,
but access remains out of reach for the patients who need it the most. Scaling
CGT operations is critical to meet the growing demand for treatment. 20 per cent
of cancer patients who are eligible for CAR-T therapies pass away while waiting
for a manufacturing slot.  

“We have to challenge the status quo, because therapies can’t just be approvable
– they need to be accessible too. More therapies approved do not automatically
translate into increases in the number of patients treated. Today, it is
estimated that less than 3 per cent of patients who could benefit from CAR-T
therapies (to name just one category) have been able to access them,” said Jason
C. Foster, CEO, Ori Biotech. 

Ori Biotech, based in London and New Jersey, has developed a proprietary,
full-stack manufacturing platform that closes, automates and standardises CGT
manufacturing. Ori is set to commercially launch its platform this year.

Manufacturing poses the biggest obstacle in the field of gene therapy. According
to SK Pharmteco, the expenses for manufacturing and cost of goods can range from
$500,000 to $1 million for gene therapy, excluding research and clinical trial
expenses, ultimately burdening patients with hefty costs. The approval of CSL
Behring’s Hemgenix, the first FDA-approved gene therapy for haemophilia B,
marked a significant milestone but also set a record for its price tag — an
eye-popping $3.5 million for a single treatment, making it the world's most
expensive drug. Similarly, Bluebird's Zynteglo, carries a list price of $2.8
million, further escalating drug pricing. Analysis by the Institute for Clinical
and Economic Review suggests that gene therapy's average cost falls between $1
million and $2 million per dose, highlighting the financial challenges
associated with accessing these innovative treatments.

The manufacturing process for CGTs is not only daunting, time-consuming, and
laborious, but there is also a significant shortage of skilled personnel to
handle the sophisticated processes required. According to BioPlan Associates'
20th Annual Report and Survey of Biopharmaceutical Manufacturing, 51.3 per cent
of the industry is facing critical shortages in manufacturing staff, more than
doubling from just 21.2 per cent in the past three years. This substantial
increase underscores the severity of the staffing shortages within the cell and
gene therapy contract manufacturing industry.

“The first manufacturing bottleneck faced by cell and gene therapy startups as
they scale up production is difficulty in hiring and retaining manufacturing
talent who can navigate the certification process, and eventually translate to
GMP manufacturing. The global competition for highly qualified manufacturing
talent is evident. The biopharma industry has long grappled with this challenge,
and it’s more challenging for startups to attract experienced talent and train
new hands in the biotech sector compared to multinational companies. Data from
Cytiva’s 2023 Global Biopharma Resilience Index shows that only 24 per cent of
biopharma executives are positive about having access to manufacturing talent
capable of working in GMP environments in the Asia Pacific,” said Krishna
Karnati, Commercial General Manager, Genomic Medicine, APAC, Cytiva.

Contract Development and Manufacturing Organisations (CDMOs) are also not fully
equipped to handle CGT manufacturing. According to Top1000bio.com database of
global biologics facilities, only a handful of the CDMOs can produce either
late-stage clinical, or commercial-scale therapies.

“Other bottlenecks include the manufacturing facilities themselves – designing
or upgrading these so they can accommodate large-scale production of cell and
gene therapies that adhere to regulatory standards, guarantee product quality,
and support adaptable production processes – and securing cell lines with the
required purity, viability, and genetic stability,” said Thomas Carlsen, CEO of
the Novo Nordisk Foundation Cellerator, Denmark. 

The Novo Nordisk Foundation Cellerator – a facility for the further development
and manufacture of cell therapies for use in clinical trials, and a hub within
the Nordic cell therapy ecosystem – is being developed to address all these
challenges. For example, the company is working to secure cell lines at an early
stage and construct a facility that is specifically designed for the large-scale
production of high-quality cell therapies. 

Unfortunately, manufacturing advancements have failed to keep pace with the
rapid innovations seen in cell and gene therapies.

“The speed of innovation in the cell and gene therapy space presents a
double-edged sword as developers bring academic-developed small-scale processes
into commercial-scale, quality-driven manufacturing environments in highly
compressed timelines. As companies try to scale production without compromising
safety and efficacy, they face three intertwining issues: scarce talent pool,
starting material variability and immature processes. Particularly in autologous
therapies, starting material is a primary source of variability impacting
manufacturing success and often heavily relies on expert personnel to tweak
process parameters; yet, this process flexibility complicates the development of
a robust manufacturing strategy that can scale across operators and
geographies,” said Dr Wenyan Leong, Strategy Lead, Asia Pacific and Japan, Cell
Therapy Technologies, Terumo Blood and Cell Technologies. 

Terumo launched the Quantum Flex bioreactor platform, one of the first systems
that enables cell therapy commercialisation from process development through
manufacturing. 

Though there isn't a singular solution to enhance the accessibility of CGTs,
refining manufacturing processes to facilitate their large-scale production can
effectively lower their costs and ensure they reach individuals in dire need of
these treatments.

 

Digitising CGT manufacturing

By automating and standardising manufacturing processes, we can initiate
large-scale production and truly industrialise CGTs. This requires the
implementation of platforms designed for flexible process discovery and smooth
translation to a commercial scale. Automation addresses key challenges such as
the inefficiency of manual processes at scale, elevated costs, and high rates of
process failure. 

“Additionally, automation cuts costs by 50 per cent and enhances quality, as
process failure rates plummet by 75 per cent due to reduced operator errors and
minimise contamination through closed processes,” said Fabian Gerlinghaus,
Co-Founder and CEO, Cellares, USA. 

Celares is set to launch its proprietary modular cGMP platform, the Cell
Shuttle, designed for industrial-scale cell therapy manufacturing. The Cell
Shuttle offers an automated manufacturing solution, slashing labour and facility
size requirements by up to 90 per cent. Bristol Myers Squibb is presently
utilising Cellares' Cell Shuttle platform for the automated proof-of-concept
manufacturing of its CAR-T therapies.

With the current manual or semi-automated manufacturing systems, production
space and the need for highly skilled operators are barriers to production
capacity. Closed and automated systems address both of these bottlenecks. To
that effect, Cytiva has partnered with robotics technology company Multiply Labs
to design a robotic system that would automate the manual portions of cell
therapy production. Lonza’s platform for autologous cell therapy manufacturing,
the Cocoon, is a functionally closed, automated system that is currently being
used to support clinical trials in Europe and North America.

“While it is known that automated and closed processing platforms will enable
scale, it has been a longstanding debate on when to adopt these sophisticated
platforms. It is preferable to choose a scalable platform early in development
to understand the parameters, and then scale rapidly as needed. One can scale-up
or scale-out depending on their manufacturing strategy. Advanced electronic
management software can help to ease scale-out strategies through integrated
data reporting and protocol management across multiple devices,” said Dr Leong. 

While the biopharma industry has embraced technology, the primary bottleneck
hindering the scale-up of cell and gene therapy (CGT) production is the absence
of comprehensive ‘end-to-end’ solutions.

“As an industry, we are still building very large facilities full of people,
using islands of automation run by and connected by people and producing data
recorded by people. There is very little ‘whole process’ automation and limited
scope for mechanisation and industrialisation, limiting productivity and
constrained by the resulting high cost of goods. To achieve production scale up,
we can take inspiration from other highly automated industries, and focus on
developing the missing links that will enable us to use these technologies in
the CGT industry and thereby achieve scale of tens of thousands of therapies a
year. Those at the more commercial end of CGT are already acutely aware that
step-change innovations are essential in order to provide these life-saving
therapies to all of the patients that can benefit from them,” said Jason Jones,
Global Business Development Lead at Cellular Origins, UK. 

Cellular Origins is working on bringing advanced robotics automation to cell
therapy for the first time. Cellular Origins’ platform is a configurable robotic
automation solution that enables scalable, cost-effective, and space-efficient
cell therapy manufacture that is designed for adaptability. 

“Technology alone will not solve the issues in a vacuum. To stride forward, we
need further collaboration between leaders in the space, to make sure that
solutions are data-driven and grounded in excellence in biology. This huge unmet
need has inspired us to partner with academics, therapeutics developers,
investors to build solutions that can help bring more therapies to more people
in urgent need,” signs off Jason Foster. 

 

Ayesha Siddiqui



SIGN UP FOR THE EDITOR PICK AND GET ARTICLES LIKE THIS DELIVERED RIGHT TO YOUR
INBOX.

Name *
Email *
Country *
Organisation *
Contact Number * +Country Code-Phone Number(xxx-xxxxxxx)
Submit




COMMENTS

×


THANK YOU

Your comment has been submitted for approval.
Please note that comments are moderated and are generally published if they are
on-topic and not abusive.
Comment
Log In To Comment   New User? Create Account















 * 
 * 
 * 
 * 

PODCAST


 

EDITORS PICKS

Addressing Accessibility an...

Can Test, Treat, Track Beat...

“AI will be integrally invo...

How Indian Biotech Investme...



PREMIUM ARTICLE

“We anticipate India will adopt dec

“Because of its specificity and sel



MOST READ

Samsung Biologics signs MoU with Se

Kimer Med inks contract worth NZD $

Queensland's Southern RNA joins for

US FDA clears Beckman Coulter Life

SURVEY BOX

Is the APAC region addressing accessibility and affordability of cell & gene
therapies?



Yes
No
May be
× Please select an option to participate in the poll.
Vote   View poll results   More polls






SUBSCRIBE TO BIOSPECTRUM ASIA




SUBSCRIBE NOW!

ENQUIRY

Thanks for contacting us! We will get in touch with you shortly.
Please fill the all fields.

Name
Email Enter a valid email address.
Phone
Message
Send message

CONTACT US

1 North Bridge Road,
#08-08 High Street Centre,
Singapore 179094

Email : communications@biospectrumasia.com

+65 90150305

Visit Our Digital Magazine

BioSpectrum India

NuFFooDS Spectrum

Privacy Policy

Sitemap

© 2024 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer

Web Interface Conceived and Powered By : SCI Knowledge Interlinks


HAVE AN ACCOUNT?

 * Login
 * Create Account
 * Forgot Password

Login
Email id
Password
Sign In
Create Account
City
First Name
Last Name
Email ID
Password
Confirm Password
Newsletter
E-magazine
Biospectrum Infomercial
Bio Resource
I accept the terms & condition & Privacy policy
Sign Up
Forgot Password
Email id
Submit
Close
×

SUBSCRIBE TO OUR NEWSLETTER

Email ID
I accept the terms & condition & Privacy policy
SUBSCRIBE!
Close